Ongoing Clinical Trials
UPMC Lupus Center of Excellence
Our comprehensive approach to treating systemic lupus erythematosus (SLE) ensures a complete and thorough diagnosis and customized treatment plan to meet each patient’s individual needs. Our multidisciplinary center provides patients with convenient access to a team of board-certified specialists in rheumatology, nephrology, dermatology, ophthalmology, and pulmonary medicine.
Our team contributes to the growing field of SLE research and treatment by engaging in NIH-funded research, clinical trials, and education of health care providers and the general public.
If you would like more information regarding ongoing clinical studies at our Center, please contact either Kevin Stiegler at 412-864-7052 or firstname.lastname@example.org.
Currently Recruiting Trials in Systemic Lupus Erythematosus (SLE)
A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE)(EMBRACE): This study is supported by Human Genome Sciences, Inc. The purpose of this study to evaluate the efficacy, safety, and tolerability of the study medication in adult SLE subjects of the black race.
A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Systemic Lupus Erythematosus (SLE) Subjects with Moderate to Severe Active Disease: This study is supported by Ablynx NV. The purpose of this study is to test if ALX-0061 is safe and effective at different dose strengths and dosing schedules when injected under the skin (subcutaneously) in people with active SLE, while standard therapy continues. Other goals of the study include potentially minimizing the risk of flares (worsening of SLE symptoms) and potentially reducing the dose of steroids (drug frequently used in SLE but which has significant side effects if taken at high doses and over a long time period), if taken as part of standard therapy.
A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Lupus Nephritis (A/Z D3461C00007): This study is supported by AstraZeneca AB. The purpose of this study is to see if anifrolumab may have an effect in treating lupus nephritis, to see how well it is tolerated, and to measure levels of anifrolumab in the blood.
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus (A/Z Protocol D3461C00004): This study is supported by AstraZeneca AB. This study is being carried out to see whether the addition of Anifrolumab (MEDI-546) to your current Lupus treatment is effective in reducing Lupus disease activity.
UPMC Lupus Center of Excellence Patient Registry: This study is supported by the University of Pittsburgh Division of Rheumatology and Clinical Immunology. The purpose of this registry is to identify patients with lupus who are interested in hearing about current and future research studies in which they may be eligible to participate. As a member of the Registry, you will have the opportunity to learn about the Center’s research projects on autoimmune disease and participate in those that may interest you and for which you may be eligible.
Currently Recruiting Trials in Sjogren’s Syndrome
A Phase 2a, Randomised, Placebo-controlled, Proof of Mechanism study to evaluate the safety and efficacy of AMG557/MEDI5872 in subjects with Primary Sjogren’s Syndrome: This study is supported by Medimmune. The main purpose of this study is to learn if the study medication reduces disease symptoms and how safe it is compared to a placebo. A placebo is an inactive substance that looks like the study medication, but does not contain any active drug. This study will also measure how much of AMG 557/MEDI5872 is in the blood and how long it takes the body to get rid of it.
Division of Rheumatology and Clinical Immunology Offices
S700 Biomedical Science Tower
3500 Terrace Street
Pittsburgh, PA 15261
412-383-8000 | Email Us